New method set to speed up protein design
Researcher from China, Germany and the US have developed a method for designing large new proteins with pre-defined properties in the lab using Alphafold2.
Author Archive for: TG
About Thomas Gabrielczyk
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 1148 entries already.
Entries by Thomas Gabrielczyk
Circio Holding ASA inks collaboration agreement with Certest Biotec SL
/in News/by Thomas GabrielczykCircio Holding ASA has inked a collaboration with Certest Biotec, SL to find and test circVec LNP-formulations to deliver its circular RNA therapeutics to target tissues for gene therapies.
Country alliance calls for EU protein strategy
/in News/by Thomas GabrielczykA dispute is brewing in Europe over climate-friendly protein production in fermenters between EU member states that are in favour of or against protein production independent of agricultural land. Germany, Denmark and supporters called on the EU Commission to formulate a European protein strategy triggering protests from farmers.
ATB Therapeutics raises €54m in Series A financing
/in News/by Thomas GabrielczykBelgian ADC specialist ATB Therapeutics BV has kicked off with €54m from EQT Life Sciences and MRL Ventures Fun to push its payload technology towards clinical development.
Tetraspecific B/NK cell better than T cell engagers
/in News/by Thomas GabrielczykInnate Pharma SA has presented promising preclinical data of its tetraspecific antibody-based B and NK cell engager IPH6501, a novel approach to treat B cell non-Hodgkin lymphoma (B-NHL).
Adaptimmune nears second approval for TCR-T therapy
/in News/by Thomas GabrielczykAfter meeting the primary endpoints of a pivotal Phase II trial, UK-based Adaptimmune Ltd. is submitting an FDA Biologics License Application for its autologous T-cell receptor therapy (TCR-T) Lete-cel (letetresgene autoleucel).
Pharmahungary Group participates in ambitious EU EVEREST Project
/in News/by Thomas GabrielczykPharmahungary Group has announced it will be participating in a project aiming to set up standardised methods to examine intercellular and interorgan communication via extracellular vesicles, the next Big thing in the diagnosis and therapy of cancer and cardiovascular diseases
Alentis Therapeutics raises US$181.4m in Series D financing
/in News/by Thomas GabrielczykSwiss Alentis Therapeutics has raised US$181.4m in an oversubscribed Series D financing set to boost clinical development of its anti-Claudin-1 ADCs in solid tumours.
Alentis Therapeutics raises US$181.4m in Series D financing
/in News/by Thomas GabrielczykSwiss Alentis Therapeutics has raised US$181.4m in an oversubscribed Series D financing set to boost clinical development of its anti-Claudin-1 ADCs in solid tumours.
Next-gen antibody formats presented at PEGS Europe
/in News/by Thomas GabrielczykBiotech CSOs, CDMOs, CROs, lab specialists and AI developers gave an in-depth insight into next-generation antibody-based therapies to about 1,500 attendees at the 16th PEGS Europe in Barcelona. Several new formats are expected to enter the market in the next few years, promising to significantly reduce the side effects of CAR-Ts, bispecific antibodies, ADCs, etc. and improve their efficacy.